Helicos Biosciences, (NASDAQ: [[ticker:HLCS]]) the Cambridge, MA-based maker of genetic analysis tools, said today that a genomics research group at Sweden’s Uppsala University has agreed to collaborate with the company’s scientists to examine changes in the nucleus of cells when they are exposed to growth factor proteins. Separately, the company announced that a U.S. cancer research center, which it didn’t name, has placed an order for the Helicos Genetic Analysis System for a research program looking at cancer stem cells.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
